Novartis Reports Results of Beovu (brolucizumab) in P-III KITE Study for Diabetic Macular Edema

Shots:

• The P-III KITE involves assessing of Beovu (brolucizumab, 6mg) vs aflibercept (2mg) in 360 patients with DME across 80 centers in 23 countries. In 2EPs, more than half of Beovu patients were maintained on a 3mos. dosing interval through year one, following the loading phase
• Results: met its 1EPs & 2EPs i.e. non-inferiority to aflibercept in mean change BCVA @52wks. & superior improvement in CST @40wks. respectively. The therapy was well-tolerated, and the rate of intraocular inflammation was equivalent between Beovu and aflibercept
• Novartis is evaluating Beovu across wet AMD, DME, retinal vein occlusion, and proliferative diabetic retinopathy and is currently conducting a second study in DME, KESTREL2, anticipating its results in late 2020

Click here ­to­ read full press release/ article | Ref: Novartis | Image: News 18